- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
|NanoSight’s founder and CTO, Dr Bob Carr|
NanoSight, world-leading manufacturers of unique nanoparticle characterization technology will host an interactive webinar on the subject of the characterization of protein aggregation. It will be held on Thursday 9th September, 0700 PDT, 1000 EDT, 1500 BST, then again live, two hours later at 0900 PDT, 1200 EDT, 1700 BST.
Characterizing aggregation in proteins is paramount in understanding both biopharmaceutical product stability and efficacy. Product quality, both in terms of biological activity and immunogenicity can be highly influenced by the state of protein aggregation. A wide variety of aggregates are encountered in biopharmaceutical samples. These may be soluble or insoluble in nature, covalent or non-covalently bonded and produced by an aggregation process which may or may not be reversible. Observed sizes of stable aggregates range from small oligomers (nanometers) to insoluble micron-sized aggregates that may contain millions of monomer units.
The objectives in characterizing aggregation include:
* Quantitatively describing degree of aggregation (concentration by size class).
* Definition of acceptable quality, in development, in process or as a release test.
* Providing insight into the mechanisms of aggregation onset, as it begins at the nanoscale.
NanoSight has recently applied Nanoparticle Tracking Analysis (NTA) to protein aggregation. This technique allows nanoscale particles, such as protein aggregates, to be directly and individually visualized and counted in liquid in real-time to provide high-resolution particle size distribution profiles.
The technique is fast, robust, accurate and low cost, representing an attractive alternative or complement to existing methods of nanoparticle analysis such as Dynamic Light Scattering, DLS (also known as Photon Correlation Spectroscopy, PCS) or Electron Microscopy.
This webinar will also describe the NTA technique and compare its strengths and limitations with other techniques currently used. The format will be interactive, aiming to give participants an opportunity to pose questions on the challenges and techniques in this important topic. The webinar will be led by Dr Bob Carr, founder and CTO of NanoSight.
To register for the webinar, visit www.nanosight.com/webinar
To learn more about nanoparticle characterization using Nanoparticle Tracking Analysis, NTA, please visit the company website (www.nanosight.com) and register for the latest issue of NanoTrail, the company's electronic newsletter.
NanoSight Limited, of Salisbury, UK, provides unique nanoparticle characterization technology. “Nanoparticle Tracking Analysis” (NTA) detects and visualizes populations of nanoparticles in liquids down to 10nm (material dependent) and measures the size of each particle from direct observations of diffusion. This particle-by-particle methodology goes beyond traditional light scattering techniques such as Dynamic Light Scattering (DLS), or Photon Correlation Spectroscopy (PCS), in providing high-resolution particle size distributions. Additionally NanoSight measures concentration and validates all data with video of particles moving under Brownian motion.
This characterization information is highly informative in understanding the more complex suspensions in biological systems, hence its wide application in development of drug delivery systems, viral vaccines, the study of toxicology of nanoparticles and their environmental fate and in biomarker detection. This real-time data also provides insight into the kinetics of protein aggregation and other time-dependent phenomena in a quantitative manner, at deeply sub-micron sizes.
NanoSight has more than 250 systems installed worldwide with users including BASF, BP, GlaxoSmithKline, Novartis, 3M Corp., Roche, Solvay and Unilever together with many universities and research institutes. There are currently 100+ third party papers citing NanoSight results, with this reference base growing very rapidly as NanoSight consolidates its key contribution to nanoparticle characterization. For more information, visit the NanoSight website (www.nanosight.com).
For more information, please click here
39 de Bohun Court
Essex CB10 2BA
T +44 (0) 1799 521881
Copyright © NanoSightIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Clues to inner atomic life from subtle light-emission shifts: Hyperfine structure of light absorption by short-lived cadmium atom isotopes reveals characteristics of the nucleus that matter for high precision detection methods July 3rd, 2015
Leti Announces Launch of First European Nanomedicine Characterisation Laboratory: Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval July 1st, 2015
Engineering the world’s smallest nanocrystal July 2nd, 2015
Newly-Developed Biosensor in Iran Detects Cocaine Addiction June 23rd, 2015